	US 11,684,656 B2
	Combination therapy for malignant diseases
Keng-Li Lan, Taipei (TW); Yi-Sheng Shih, Taipei (TW); Keng-Hsueh Lan, Taipei (TW); Sung-Hsin Kuo, Taipei (TW); and Weng-Shiang Chen, Taipei (TW)
Assigned to TAIPEI VETERANS GENERAL HOSPITAL, Taipei (TW)
Appl. No. 15/773,433
Filed by Taipei Veterans General Hospital, Taipei (TW)
PCT Filed Nov. 4, 2016, PCT No. PCT/CN2016/104763 § 371(c)(1), (2) Date May 3, 2018, PCT Pub. No. WO2017/076360, PCT Pub. Date May 11, 2017.
Claims priority of provisional application 62/250,984, filed on Nov. 4, 2015.
Prior Publication US 2018/0319861 A1, Nov. 8, 2018
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 38/17 (2006.01); C07K 14/705 (2006.01); A61K 39/39 (2006.01)

CPC A61K 39/0011 (2013.01) [A61K 38/1774 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); C07K 14/70521 (2013.01); C07K 14/70596 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); C07K 2317/76 (2013.01)]

6 Claims

1. A method for treating a malignant disease in a subject, comprising administering to said subject a vaccine in combination with a radiation treatment, in which the vaccine is a pharmaceutical composition comprising a DNA construct comprising a polynucleotide sequence encoding Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and a PD-1 or a programmed cell death 1 ligand 1 (PD-L1), or combination thereof, wherein the malignant disease is colorectal cancer.